Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

Michael Duffey, PhD

  • Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Michael Duffey (Co-Investigator), Mark Parker (Principal Investigator), Sangita Patel (Co-Investigator). NIH National Eye Institute. $1,972,804. 2/1/2018-1/1/2023.
  • Investigating the Action and Physiological Role of Slc4a11 in the Cornea (NIH R01 EY028580). Michael Duffey (Co-Investigator), Mark Parker (Principal Investigator), Sangita Patel (Co-Investigator). NIH. 1/1/2018-1/1/2023.

Jian Feng, PhD

  • A Novel Epigenetic Mechanism for Alzheimer's Disease. Jian Feng (Co-Investigator), Zhen Yan (Principal Investigator). NIH. $1,993,750. 4/1/2017-3/1/2022.
  • Kinetic Barriers of Transdifferentiation. Jian Feng (Principal Investigator). Department of Veterans Affairs. 4/1/2014-3/1/2018.

Wilma Hofmann, PhD

  • Role of myosin IC in prostate cancer metastasis. Wilma Hofmann (Principal Investigator). NIH/NCI. $478,500. 8/1/2017-7/1/2020.
  • Defining the link between obesity and aggressive prostate cancer. Wilma Hofmann (Principal Investigator). DoD CDMRP. $598,000. 9/1/2014-9/1/2017.

Mark Parker, PhD

  • Renal considerations in the heat stress and hydration recommendations. Mark Parker (Co-Investigator). NIH National Institute for Occupational Safety and Health. 9/1/2019-8/1/2024.
  • Investigating the Action and Physiological Role of Slc4a11 in the Cornea. Mark Parker (Principal Investigator), Michael Duffey (Co-Investigator), Sangita Patel (Co-Investigator). NIH National Eye Institute. $1,972,804. 2/1/2018-1/1/2023.
  • Investigating the Action and Physiological Role of Slc4a11 in the Cornea (NIH R01 EY028580). Mark Parker (Principal Investigator), Michael Duffey (Co-Investigator), Sangita Patel (Co-Investigator). NIH. 1/1/2018-1/1/2023.

Brian Weil, PhD

  • Preclinical Evaluation of Systemic Cellular Postconditioning as a Novel Cardioprotective and Neuroprotective Therapy Following Cardiac Arrest. Brian Weil (Principal Investigator). The ZOLL Foundation. 12/1/2018-11/1/2019.
  • Novel Biomarkers of Extracellular Matrix Expansion and Interstitial Fibrosis in Heart Failure. Brian Weil (Principal Investigator). The Community Foundation for Greater Buffalo. 11/1/2018-10/1/2019.
  • T3np in Cardiac Resuscitation – Pivotal Pre-Clinical Trial. Brian Weil (Principal Investigator). UB Center for Advanced Biomedical and Bioengineering Technology. 7/1/2018-6/1/2020.
  • Pathophysiology of Myocardial Remodeling in Heart Failure With Preserved Ejection Fraction. Brian Weil (Principal Investigator). American Heart Association. 7/1/2017-6/1/2020.

Zhen Yan, PhD

  • NEW TREATMENT STRATEGY FOR ALZHEIMER'S DISEASE. Zhen Yan (Co-Principal Investigator). NIH. $438,625. 4/1/2020-3/1/2022.
  • A Novel Epigenetic Mechanism for Alzheimer's Disease. Zhen Yan (Principal Investigator), Jian Feng (Co-Investigator). NIH. $1,993,750. 4/1/2017-3/1/2022.
  • Novel Therapeutic Strategies for Autism. Zhen Yan (Principal Investigator). Nancy Lurie Marks Family Foundation. $540,000. 2/1/2016-1/1/2019.
  • Physiological and Pathophysiological Basis of Stress. Zhen Yan (Principal Investigator). NIH. $1,993,750. 8/1/2015-7/1/2020.
  • Functions of D4 Dopamine Receptors in Prefrontal Cortex. Zhen Yan (Principal Investigator). NIH. $1,590,000. 7/1/2014-6/1/2019.
  • A Novel Pathophysiological Mechanism of Alzheimer's Disease. Zhen Yan (Principal Investigator). Department of Veterans Affairs. $600,000. 4/1/2013-9/1/2017.